Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases
GL Sequiera, A Srivastava, N Sareen, W Yan… - Science …, 2022 - science.org
A “Leap-of-Faith” approach is used to treat patients with previously unknown ultrarare
pathogenic mutations, often based on evidence from patients having dissimilar but more …
pathogenic mutations, often based on evidence from patients having dissimilar but more …
Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases
GL Sequiera, A Srivastava, N Sareen… - Science …, 2022 - ui.adsabs.harvard.edu
Abstract A" Leap-of-Faith" approach is used to treat patients with previously unknown
ultrarare pathogenic mutations, often based on evidence from patients having dissimilar but …
ultrarare pathogenic mutations, often based on evidence from patients having dissimilar but …
[PDF][PDF] Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases
GL Sequiera, A Srivastava, N Sareen, W Yan… - 2022 - pdfs.semanticscholar.org
A “Leap-of-Faith” approach is used to treat patients with previously unknown ultrarare
pathogenic mutations, often based on evidence from patients having dissimilar but more …
pathogenic mutations, often based on evidence from patients having dissimilar but more …
[HTML][HTML] Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases
GL Sequiera, A Srivastava, N Sareen, W Yan… - Science …, 2022 - ncbi.nlm.nih.gov
Abstract A “Leap-of-Faith” approach is used to treat patients with previously unknown
ultrarare pathogenic mutations, often based on evidence from patients having dissimilar but …
ultrarare pathogenic mutations, often based on evidence from patients having dissimilar but …
Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases.
GL Sequiera, A Srivastava, N Sareen, W Yan… - Science …, 2022 - europepmc.org
Abstract A “Leap-of-Faith” approach is used to treat patients with previously unknown
ultrarare pathogenic mutations, often based on evidence from patients having dissimilar but …
ultrarare pathogenic mutations, often based on evidence from patients having dissimilar but …
[PDF][PDF] Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases
GL Sequiera, A Srivastava, N Sareen, W Yan… - 2022 - researchgate.net
A “Leap-of-Faith” approach is used to treat patients with previously unknown ultrarare
pathogenic mutations, often based on evidence from patients having dissimilar but more …
pathogenic mutations, often based on evidence from patients having dissimilar but more …
[PDF][PDF] Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases
GL Sequiera, A Srivastava, N Sareen, W Yan… - 2022 - axionbiosystems.com
A “Leap-of-Faith” approach is used to treat patients with previously unknown ultrarare
pathogenic mutations, often based on evidence from patients having dissimilar but more …
pathogenic mutations, often based on evidence from patients having dissimilar but more …
Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases
GL Sequiera, A Srivastava, N Sareen… - Science …, 2022 - pubmed.ncbi.nlm.nih.gov
A" Leap-of-Faith" approach is used to treat patients with previously unknown ultrarare
pathogenic mutations, often based on evidence from patients having dissimilar but more …
pathogenic mutations, often based on evidence from patients having dissimilar but more …